Cobra to produce monoclonal antibody products for Alligator
Will provide cell line development, scale-up, GMP supplies and stability studies
Cobra Biologics, a manufacturer of biologics and pharmaceuticals with cGMP facilities in Sweden and the UK, has won a manufacturing services and supply contract with Alligator Bioscience for the production of monoclonal antibody drug substance and drug product for pre-clinical studies and Phase I–II clinical trials.
Alligator Bioscience, a privately held firm based in Lund, Sweden, develops biotherapeutics for cancer and has three proprietary products in its pipeline.
Under the terms of the agreement, Cobra will provide cell line development through its maxXpress service, GMP cell banking, analytical and process development, scale-up, toxicology and GMP supplies, as well as stability studies and QP release for clinical trials.
